J. Brogdon

发表

A Nonproliferating Parvovirus Vaccine Vector Elicits Sustained, Protective Humoral Immunity following a Single Intravenous or Intranasal Inoculation

P. Tattersall, G. Palmer, J. Brogdon, 2004, Journal of Virology.

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

G. Dranoff, J. Brogdon, N. Wilson, 2013, The Journal of experimental medicine.

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

G. Dranoff, J. Brogdon, N. Wilson, 2014, Immunology and cell biology.

Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells

Yong Gu Lee, Nathan H. Roy, S. Grupp, 2021, Nature Medicine.

An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity.

Carla P. Guimarães, M. Hild, Jeff Porter, 2020, Cell chemical biology.

Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL

D. Teachey, S. Grupp, D. Porter, 2015 .

Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay

Irene L. Ch’en, J. Brogdon, Nathan J. Riccitelli, 2020, Molecular therapy. Methods & clinical development.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Weiss, Iulian Pruteanu-Malinici, B. Levine, 2019, The Journal of clinical investigation.

Activation of CD4 T cells by Raf-independent effectors of Ras

R. Flavell, J. Brogdon, O. Henegariu, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Transcription in Naive CD4+ T Cells Regulates NFATc/p Activity and Early IL-4 The Potency of TCR Signaling Differentially

J. Brogdon, K. Bottomly, D. Leitenberg, 2013 .

Transcription in Naive CD 4 Regulates NFATc / p Activity and Early IL-4 The Potency of TCR Signaling Differentially

J. Brogdon, K. Bottomly, D. Leitenberg, 2002 .

A Site for CD 4 Binding in the b 1 Domain of the MHC Class II Protein HLA-DR 1 1

J. Brogdon, C. Doyle, D. Eckels, 1998 .

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Amanda M Li, D. Teachey, S. Grupp, 2017 .

CD4-Dependent Signaling Is Required for a Late Checkpoint during Th2 Development Associated with Resistance to Activation-Induced Cell Death1

K. Tinsley, J. Brogdon, D. Leitenberg, 2005, The Journal of Immunology.

Activation-Induced Cell Death Associated with Resistance to Late Checkpoint during Th 2 Development CD 4-Dependent Signaling Is Required for a

K. Tinsley, J. Brogdon, D. Leitenberg, 2005 .

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

Na Li, Andreas Loew, Gabriela Plesa, 2015, Science Translational Medicine.

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Sadik H. Kassim, E. Wherry, F. Johnson, 2021, Nature medicine.

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Gregory M. Chen, F. Bushman, E. Wherry, 2022, Nature.

Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas

Stephen J. Schuster, David L. Porter, Jakub Svoboda, 2017, The New England journal of medicine.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Hans Bitter, Wei-Ting Hwang, Iulian Pruteanu-Malinici, 2018, Nature Medicine.

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

Hans Bitter, Kevin Nguyen, Wendy Winckler, 2018, Nature Medicine.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

K. Mansfield, S. Brem, D. O’Rourke, 2017, Science Translational Medicine.

The Potency of TCR Signaling Differentially Regulates NFATc/p Activity and Early IL-4 Transcription in Naive CD4+ T Cells1

Kim Bottomly, David Leitenberg, J. Brogdon, 2002, The Journal of Immunology.

Regulation of Early IL-4 Expression in Naive Signal-Regulated Kinase Activation in the Role of TCR-Induced Extracellular

J. Brogdon, K. Bottomly, P. Jorritsma, 2013 .

Role of TCR-Induced Extracellular Signal-Regulated Kinase Activation in the Regulation of Early IL-4 Expression in Naive CD4+ T Cells1

J. Brogdon, K. Bottomly, P. Jorritsma, 2003, The Journal of Immunology.

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

S. Szabo, D. Cohen, J. Brogdon, 2007, Blood.

Qian of Th 1 but not Th 2 effector cell function Histone deacetylase activities are required for innate immune cell control

S. Szabo, D. Cohen, J. Brogdon, 2006 .

Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ.

J. Brogdon, S. Constant, I. Visintin, 2002, The Journal of clinical investigation.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Sadik H. Kassim, E. Wherry, H. Bitter, 2018, Nature Medicine.

CD4 Raft Association and Signaling Regulate Molecular Clustering at the Immunological Synapse Site1

J. Brogdon, F. Balamuth, K. Bottomly, 2004, The Journal of Immunology.

In vivo discovery of immunotherapy targets in the tumour microenvironment

J. C. Love, N. Hacohen, D. Root, 2014, Nature.

Rationale for anti-GITR cancer immunotherapy.

J. Brogdon, D. Knee, B. Hewes, 2016, European journal of cancer.

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

J. Byrd, D. Porter, B. Levine, 2022, Blood advances.

Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells

Gregory M. Chen, F. Bushman, E. Wherry, 2021, bioRxiv.

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

J. Briones, I. Flinn, U. Jaeger, 2021, Blood.

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

G. Wertheim, D. Teachey, S. Grupp, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.

D. Teachey, S. Grupp, D. Porter, 2016 .

A Site for CD4 Binding in the β1 Domain of the MHC Class II Protein HLA-DR1

S. White, J. Brogdon, C. Doyle, 1998, The Journal of Immunology.

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

B. Levine, C. June, J. Melenhorst, 2019, Blood.

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

B. Levine, C. June, J. Melenhorst, 2019, Blood.

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

E. Wherry, F. Johnson, H. Bitter, 2017 .

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

G. Linette, C. June, W. Hwang, 2022, Blood cancer discovery.

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Nathan H. Roy, S. Grupp, C. June, 2019, Blood.

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

S. Grupp, D. Porter, C. June, 2017 .

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

G. Wertheim, S. Grupp, B. Engels, 2022, Blood.

Two Cases of Severe Pulmonary Toxicity from Highly Active Mesothelin-Directed CAR T Cells.

Ryan J. Golden, C. June, Xiaojun Liu, 2023, Molecular therapy : the journal of the American Society of Gene Therapy.

Preservation of T-Cell Stemness with a Novel Expansionless CAR-T Manufacturing Process, Which Reduces Manufacturing Time to Less Than Two Days, Drives Enhanced CAR-T Cell Efficacy

Jennifer Yang, B. Engels, J. Brogdon, 2021, Blood.

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Shannon R. McCurdy, D. Porter, B. Levine, 2021, Blood.

Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-Charge TM Platform for the Treatment of Multiple Myeloma

Carla P. Guimarães, J. Brogdon, Poonam Vaidya, 2021, Blood.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

J. Briones, I. Flinn, D. Blaise, 2023, Cancer discovery.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Iulian Pruteanu-Malinici, W. Hwang, J. Brogdon, 2019, The Journal of clinical investigation.